Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Multiparametric senescent cell phenotyping reveals targets of senolytic therapy in the aged murine skeleton

Open access

Published version of a preprint

Abstract

Senescence drives organismal aging, yet the deep characterization of senescent cells in vivo remains incomplete. Here, we apply mass cytometry by time-of-flight using carefully validated antibodies to analyze senescent cells at single-cell resolution. We use multiple criteria to identify senescent mesenchymal cells that are growth-arrested and resistant to apoptosis. These p16 + Ki67-BCL-2+ cells are highly enriched for senescence-associated secretory phenotype and DNA damage markers, are strongly associated with age, and their percentages are increased in late osteoblasts/osteocytes and CD24 high osteolineage cells. Moreover, both late osteoblasts/osteocytes and CD24 high osteolineage cells are robustly cleared by genetic and pharmacologic senolytic therapies in aged mice. Following isolation, CD24+ skeletal cells exhibit growth arrest, senescence-associated β-galactosidase positivity, and impaired osteogenesis in vitro. These studies thus provide an approach using multiplexed protein profiling to define senescent mesenchymal cells in vivo and identify specific skeletal cell populations cleared by senolytics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-40393-9

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Validation of antibodies and detection of senescent cells by CyTOF. a Experimental workflow of single mouse protein expression in U2OS cells for the testing of CyTOF antibodies; b qPCR analysis confirming upregulated mouse p16Ink4a mRNA (Cdkn2a) after expression vector transfection (n = 3 independently run experiments; mean ± SD); c CyTOF dot plots of expression samples testing different p16 antibodies, demonstrating outcomes of both failed (antibody #1) and successful (antibody #2) tests; d Schematic of testing senescence-specific CyTOF antibodies using etoposide-treated mouse BMSCs with qPCR confirmation of upregulated p16Ink4a (Cdkn2aINK) and p21Cip1 (Cdkn1a) transcripts (n = 3 independently run experiments; mean ± SD); e CyTOF plots of p16 and p21 protein expression, demonstrating increased percent-positive cells with etoposide treatment; f Fold-change of percent-positive values for each of the senescence panel markers in etoposide-treated cells, where dotted line represents values from vehicle. g Schematic of bone and marrow mesenchymal cell isolation and CyTOF workflow; h Gating strategy for p16+ cells using similarly processed cells from p16-null mice as a negative control (i) Quantification of %p16+ and (j) %p21+ cells in young and old mice (n = 15 young and n = 12 old biologically independent animals). Schematics in (a, d, g) were generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. (d) Multiple two-sided t tests with Holm-Sidak Correction. (i, j) Two-sided Mann-Whitney test. Source data are provided as a Source Data file.
Fig. 1 Validation of antibodies and detection of senescent cells by CyTOF. a Experimental workflow of single mouse protein expression in U2OS cells for the testing of CyTOF antibodies; b qPCR analysis confirming upregulated mouse p16Ink4a mRNA (Cdkn2a) after expression vector transfection (n = 3 independently run experiments; mean ± SD); c CyTOF dot plots of expression samples testing different p16 antibodies, demonstrating outcomes of both failed (antibody #1) and successful (antibody #2) tests; d Schematic of testing senescence-specific CyTOF antibodies using etoposide-treated mouse BMSCs with qPCR confirmation of upregulated p16Ink4a (Cdkn2aINK) and p21Cip1 (Cdkn1a) transcripts (n = 3 independently run experiments; mean ± SD); e CyTOF plots of p16 and p21 protein expression, demonstrating increased percent-positive cells with etoposide treatment; f Fold-change of percent-positive values for each of the senescence panel markers in etoposide-treated cells, where dotted line represents values from vehicle. g Schematic of bone and marrow mesenchymal cell isolation and CyTOF workflow; h Gating strategy for p16+ cells using similarly processed cells from p16-null mice as a negative control (i) Quantification of %p16+ and (j) %p21+ cells in young and old mice (n = 15 young and n = 12 old biologically independent animals). Schematics in (a, d, g) were generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. (d) Multiple two-sided t tests with Holm-Sidak Correction. (i, j) Two-sided Mann-Whitney test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 2 BCL-2 expression defines p16+ cells with senescent characteristics. a Schematic of multidimensional p16+ senescent cell analysis workflow; b UMAP visualization and FlowSOM clustering of pooled p16+ cells from young (n = 15) and old (n = 12) mice with c bar graphs indicating percent-of-whole cluster abundance changes. d FlowSOM clusters ranked by descending Ki67 mean expression plotted against p16 mean expression (Log2 Fold-Change). e Gating strategy for p16 + BCL2+ cells and f quantification of %Ki67+ and Ki67 mean expression alongside p16- and total p16+ cells. g Volcano plots of age-related changes in mean senescence marker expression within p16+ cells and quantification of % BCL-2+ cells and mean BCL-2 expression within all p16+ cells with age; h Gating strategy for “p16KB” cells; i Heatmap representation of protein expression between p16KB cells and non-senescent p16- cells, with asterisks indicating significance (*p < 0.05, **p < 0.01). Columns within each population represent a biological replicate (n = 12 Old). j Quantification of p16KB cells with age and numerical comparison to total p16+ cells (n = 15 young and n = 12 old biologically independent animals). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. (f, g [volcano plot]) Multiple two-sided t tests with Holm-Sidak Correction. (g, i, j) Two-sided Mann–Whitney test. Source data are provided as a Source Data file.
Fig. 2 BCL-2 expression defines p16+ cells with senescent characteristics. a Schematic of multidimensional p16+ senescent cell analysis workflow; b UMAP visualization and FlowSOM clustering of pooled p16+ cells from young (n = 15) and old (n = 12) mice with c bar graphs indicating percent-of-whole cluster abundance changes. d FlowSOM clusters ranked by descending Ki67 mean expression plotted against p16 mean expression (Log2 Fold-Change). e Gating strategy for p16 + BCL2+ cells and f quantification of %Ki67+ and Ki67 mean expression alongside p16- and total p16+ cells. g Volcano plots of age-related changes in mean senescence marker expression within p16+ cells and quantification of % BCL-2+ cells and mean BCL-2 expression within all p16+ cells with age; h Gating strategy for “p16KB” cells; i Heatmap representation of protein expression between p16KB cells and non-senescent p16- cells, with asterisks indicating significance (*p < 0.05, **p < 0.01). Columns within each population represent a biological replicate (n = 12 Old). j Quantification of p16KB cells with age and numerical comparison to total p16+ cells (n = 15 young and n = 12 old biologically independent animals). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. (f, g [volcano plot]) Multiple two-sided t tests with Holm-Sidak Correction. (g, i, j) Two-sided Mann–Whitney test. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 3 CD24high osteolineage cells represent inflammatory senescent cells in old mice targeted by genetic senolytic clearance. a t-SNE visualization and FlowSOM clustering of n = 80,000 CD45-Lin- bone and marrow cells (n = 40 INK-ATTAC mice [n = 15 young, n = 12 old + vehicle, n = 13 old + AP] – 2,000 cells sampled per mouse) analyzed by CyTOF. Cells are colored by clustered population (see Table 1 for defining markers); b Heatmap representation of the 11 cell clusters and protein expression of identification markers; c Log2 fold-Change mean expression of p16 or BCL-2 in each cluster with age. d Log2 fold-change of %p16KB cells in each cluster across aging; e Schematic of p16+ senescent cell clearance in 24-month-old AP-treated INK-ATTAC mice; f t-SNE plots of FlowSOM clusters of bone/bone marrow cells from old vehicle- or AP-treated INK-ATTAC mice. Black arrows indicate cleared clusters while green arrows indicate increased cluster abundance; g Quantification of cluster abundance changes between vehicle- and AP-treated mice (Log2-fold change to vehicle); h CD24 expression feature plots in samples from vehicle- or AP-treated mice; i Feature plots of p16 and FLAG (INK-ATTAC transgene) protein expression; j Heatmap and k, l volcano plots for statistical comparisons of senescence marker expression between cleared clusters in vehicle-treated old mice. Schematic in (e) was generated using BioRender. Box plots show median and interquartile ranges with error bars representing minimum and maximum values. (c, d, g) Two-sided Mann–Whitney test or unpaired t test, as appropriate. k, l Multiple two-sided t tests with Holm-Sidak Correction. Source data are provided as a Source Data file.
Fig. 3 CD24high osteolineage cells represent inflammatory senescent cells in old mice targeted by genetic senolytic clearance. a t-SNE visualization and FlowSOM clustering of n = 80,000 CD45-Lin- bone and marrow cells (n = 40 INK-ATTAC mice [n = 15 young, n = 12 old + vehicle, n = 13 old + AP] – 2,000 cells sampled per mouse) analyzed by CyTOF. Cells are colored by clustered population (see Table 1 for defining markers); b Heatmap representation of the 11 cell clusters and protein expression of identification markers; c Log2 fold-Change mean expression of p16 or BCL-2 in each cluster with age. d Log2 fold-change of %p16KB cells in each cluster across aging; e Schematic of p16+ senescent cell clearance in 24-month-old AP-treated INK-ATTAC mice; f t-SNE plots of FlowSOM clusters of bone/bone marrow cells from old vehicle- or AP-treated INK-ATTAC mice. Black arrows indicate cleared clusters while green arrows indicate increased cluster abundance; g Quantification of cluster abundance changes between vehicle- and AP-treated mice (Log2-fold change to vehicle); h CD24 expression feature plots in samples from vehicle- or AP-treated mice; i Feature plots of p16 and FLAG (INK-ATTAC transgene) protein expression; j Heatmap and k, l volcano plots for statistical comparisons of senescence marker expression between cleared clusters in vehicle-treated old mice. Schematic in (e) was generated using BioRender. Box plots show median and interquartile ranges with error bars representing minimum and maximum values. (c, d, g) Two-sided Mann–Whitney test or unpaired t test, as appropriate. k, l Multiple two-sided t tests with Holm-Sidak Correction. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 4 CD24 osteolineage cells display an age-related senescence expression profile. a Schematic of CITRUS analysis workflow; b Aging markers upregulated in the highest number of CITRUS clusters with age (FDR < 5%); c Senescence/SASP marker expression changes across aging overlaid on CITRUS plot (each circle is a cluster, grouped by cluster families dotted lines; see Supplementary Fig. 6A for identity marker expression). Red clusters indicate upregulated p16 expression, while colored overlays indicate upregulation in the corresponding SASP marker. All markers converge in CD24+/Runx2+/Osterix+ clusters, indicating that this population exhibits the most widespread age-related increase in SASP marker expression in bone/bone marrow. Box plot below demonstrates the upregulation of %p16KB cells with age in this population. Red arrows point to d quantified median expression of various SASP factors in the CD24+/Runx2+/Osterix+ clusters with age (mean ± SD) and e overlay of the CD24+/Runx2+/Osterix+ cluster on original t-SNE plot with FlowSOM clusters labeled (c, d) n = 15 young and n = 12 old biologically independent animals; f UMAP visualization by scRNA-seq of n = 3,362 clustered Lin-CD45- cells from the digested bone and marrow of n = 3 24-month untreated male INK-ATTAC mice; CAR, Cxcl12-abundant reticular; g Density plots of CD24 osteolineage markers and anti-apoptotic factors (Bcl2, Bcl2l1, Bcl2l2). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. c Two-sided Mann–Whitney test. d Multiple two-sided t-tests with Holm-Sidak Correction. Source data are provided as a Source Data file.
Fig. 4 CD24 osteolineage cells display an age-related senescence expression profile. a Schematic of CITRUS analysis workflow; b Aging markers upregulated in the highest number of CITRUS clusters with age (FDR < 5%); c Senescence/SASP marker expression changes across aging overlaid on CITRUS plot (each circle is a cluster, grouped by cluster families dotted lines; see Supplementary Fig. 6A for identity marker expression). Red clusters indicate upregulated p16 expression, while colored overlays indicate upregulation in the corresponding SASP marker. All markers converge in CD24+/Runx2+/Osterix+ clusters, indicating that this population exhibits the most widespread age-related increase in SASP marker expression in bone/bone marrow. Box plot below demonstrates the upregulation of %p16KB cells with age in this population. Red arrows point to d quantified median expression of various SASP factors in the CD24+/Runx2+/Osterix+ clusters with age (mean ± SD) and e overlay of the CD24+/Runx2+/Osterix+ cluster on original t-SNE plot with FlowSOM clusters labeled (c, d) n = 15 young and n = 12 old biologically independent animals; f UMAP visualization by scRNA-seq of n = 3,362 clustered Lin-CD45- cells from the digested bone and marrow of n = 3 24-month untreated male INK-ATTAC mice; CAR, Cxcl12-abundant reticular; g Density plots of CD24 osteolineage markers and anti-apoptotic factors (Bcl2, Bcl2l1, Bcl2l2). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. c Two-sided Mann–Whitney test. d Multiple two-sided t-tests with Holm-Sidak Correction. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 5 Pharmacologic senolytic therapy targets CD24+ osteolineage cells in aged mice. a Experimental design of pharmacological senolytic treatment of 24-month-old C57BL/6 N mice with Dasatinib + Quercetin (D + Q). Mice were treated for 3 consecutive days (n = 15 old + vehicle and n = 16 old + D + Q biologically independent animals), then harvested at 14 days (indicated by dashes); b Quantified cell abundance changes with D + Q treatment in clusters similarly targeted in INK-ATTAC mice (See Supplementary Fig. 9A, B for cluster definitions); c, d CITRUS analysis of cluster abundance (c) and median expression changes (d) between vehicle- and D + Q-treated mice (FDR < 5%). c Cleared clusters, marked by blue, are defined by high CD24, Osterix, and/or Runx2 expression, as shown by histograms. d Clusters with reduced median expression are colored by their respective marker, with box plots demonstrating expression changes (Mann–Whitney test). Cluster families are marked by dotted lines (See Supplementary Fig. 9C for defining markers); e Gating strategy for CD45-CD24+ and – populations from all cells in CyTOF data from INK-ATTAC mice treated with vehicle or AP (n = 12 vehicle, n = 13 AP), and C57BL/6 N mice treated with vehicle or D + Q (n = 15 vehicle and n = 16 D + Q); f Quantification of cell population percentages demonstrate both senolytic treatments clear CD45-CD24+ cells, but not CD45-CD24- or (g) CD45 + CD24+ cells (mean ± SD). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. b, g Two-sided Mann–Whitney or unpaired t test, as appropriate; f Multiple two-sided t tests with Holm–Sidak Correction. Source data are provided as a Source Data file.
Fig. 5 Pharmacologic senolytic therapy targets CD24+ osteolineage cells in aged mice. a Experimental design of pharmacological senolytic treatment of 24-month-old C57BL/6 N mice with Dasatinib + Quercetin (D + Q). Mice were treated for 3 consecutive days (n = 15 old + vehicle and n = 16 old + D + Q biologically independent animals), then harvested at 14 days (indicated by dashes); b Quantified cell abundance changes with D + Q treatment in clusters similarly targeted in INK-ATTAC mice (See Supplementary Fig. 9A, B for cluster definitions); c, d CITRUS analysis of cluster abundance (c) and median expression changes (d) between vehicle- and D + Q-treated mice (FDR < 5%). c Cleared clusters, marked by blue, are defined by high CD24, Osterix, and/or Runx2 expression, as shown by histograms. d Clusters with reduced median expression are colored by their respective marker, with box plots demonstrating expression changes (Mann–Whitney test). Cluster families are marked by dotted lines (See Supplementary Fig. 9C for defining markers); e Gating strategy for CD45-CD24+ and – populations from all cells in CyTOF data from INK-ATTAC mice treated with vehicle or AP (n = 12 vehicle, n = 13 AP), and C57BL/6 N mice treated with vehicle or D + Q (n = 15 vehicle and n = 16 D + Q); f Quantification of cell population percentages demonstrate both senolytic treatments clear CD45-CD24+ cells, but not CD45-CD24- or (g) CD45 + CD24+ cells (mean ± SD). Schematic in (a) was generated using BioRender. Box plots show median and interquartile range with error bars representing minimum and maximum values. b, g Two-sided Mann–Whitney or unpaired t test, as appropriate; f Multiple two-sided t tests with Holm–Sidak Correction. Source data are provided as a Source Data file.CC BY · PubMed Central
Fig. 6 Isolated CD24+ bone stromal cells exhibit functional characteristics of senescence and impaired osteogenesis. a Gating strategy for FACS isolation of CD24+ and CD24− skeletal stromal cells from Lin-depleted bone/marrow cell suspensions; b Gating strategy and c quantification of cell cycle analysis of CD24+/− cells (n = 7 mice); d Outline of in vitro senescence phenotyping of CD24+/− cells; I Brightfield images and quantification of colony formation efficiency (CFE) assay and SA-β-gal staining of CD24- and CD24+ cells after 7 or 14 days in culture, respectively (n = 3 mice); f Outline of osteoblast differentiation assays of CD24+/− cells; g CD24- and + cell monolayers stained with either alkaline phosphatase (ALP) or Alizarin Red after 14 and 21 days in culture, respectively. Accompanying high magnification images are 20X (n = 3 mice); h Schematic of in vitro etoposide-induced senescence of BMSCs; I MRNA levels of Cdkn2aINK (p16), Cdkn1a (p21), and Cd24a (CD24) from BMSCs treated with vehicle (DMSO) or etoposide (n = 3 mice). Schematic in (h) was generated using BioRender. Scale bars represent 750 μm. Bars show mean ± SD (c, e). Two-sided unpaired t-test or Mann–Whitney test as appropriate; (i) Multiple two-sided t tests with Holm–Sidak Correction. Source data are provided as a Source Data file.
Fig. 6 Isolated CD24+ bone stromal cells exhibit functional characteristics of senescence and impaired osteogenesis. a Gating strategy for FACS isolation of CD24+ and CD24− skeletal stromal cells from Lin-depleted bone/marrow cell suspensions; b Gating strategy and c quantification of cell cycle analysis of CD24+/− cells (n = 7 mice); d Outline of in vitro senescence phenotyping of CD24+/− cells; I Brightfield images and quantification of colony formation efficiency (CFE) assay and SA-β-gal staining of CD24- and CD24+ cells after 7 or 14 days in culture, respectively (n = 3 mice); f Outline of osteoblast differentiation assays of CD24+/− cells; g CD24- and + cell monolayers stained with either alkaline phosphatase (ALP) or Alizarin Red after 14 and 21 days in culture, respectively. Accompanying high magnification images are 20X (n = 3 mice); h Schematic of in vitro etoposide-induced senescence of BMSCs; I MRNA levels of Cdkn2aINK (p16), Cdkn1a (p21), and Cd24a (CD24) from BMSCs treated with vehicle (DMSO) or etoposide (n = 3 mice). Schematic in (h) was generated using BioRender. Scale bars represent 750 μm. Bars show mean ± SD (c, e). Two-sided unpaired t-test or Mann–Whitney test as appropriate; (i) Multiple two-sided t tests with Holm–Sidak Correction. Source data are provided as a Source Data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 134 references

Cited by

See all 60

Metadata

Authors
Doolittle, M. L., Saul, D., Kaur, J., Rowsey, J. L., Vos, S. J., Pavelko, K. D., Farr, J. N., Monroe, D. G., & Khosla, S.
Affiliations
Mayo Clinic (US)
Corresponding author
Khosla, Sundeep
Venue
Nature Communications
Published
2023-07-31
Volume
14
Issue
1
Pages
4587-4587
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4385426207
Cited by
57
References
134
Citations by year
2026: 16 · 2025: 16 · 2024: 21 · 2023: 4
FWCI
10.07
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by-nc-nd)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Department of Health & Human Services | NIH | National Institute on Aging (P01 AG062413, R01 AG076515, U54 AG079754, R01 AG063707, T32 AG049672)
  • U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128552)
  • American Federation for Aging Research
  • Deutsche Forschungsgemeinschaft (D.F.G., 413501650)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
Keywords
cellular senescence, senolytic therapy, senescent cells, bone aging, osteoblasts, osteocytes, senescence-associated secretory phenotype, p16, Ki-67, Bcl-2, mass cytometry, bone formation, growth arrest, DNA damage, senolytics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multiparametric senescent cell phenotyping reveals targets of senolytic therapy in the aged murine skeleton. https://app.cochat.ai/papers/10.1038/s41467-023-40393-9
The paper
Doolittle, M. L., Saul, D., Kaur, J., Rowsey, J. L., Vos, S. J., Pavelko, K. D., Farr, J. N., Monroe, D. G., & Khosla, S. (2023). Multiparametric senescent cell phenotyping reveals targets of senolytic therapy in the aged murine skeleton. Nature Communications. https://doi.org/10.1038/s41467-023-40393-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.